Lilly's GLP-1 pill seen as superior in head-to-head trial

Breakdown

• Lilly's GLP-1 pill orfoglipron outperformed Novo's in a phase three diabetes trial.
• Lilly's pill reduced blood sugar by 2.2% and weight by 9%, compared to 1.4% and 5% for Novo's. 15s
• Lilly used a lower dose than Novo plans to use for weight loss, affecting direct comparison. 27s
• Novo's pill is already approved at the tested dose for diabetes, but a higher dose is under review for obesity. 37s
• Lilly's orfoglipron has exceeded expectations in three out of four studies, according to company scientists. 55s